Orthocell’s entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in the article “Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada”.
The article outlines the swift transition from approval to revenue generation in this new market, and points to Striate+’s strong market acceptance and potential.
Here’s an excerpt:
“Strong sales traction in the existing markets has been driven by BioHorizons’ comprehensive marketing and medical education program, which has effectively informed clinicians about the benefits of Striate+.
This success is further supported by Striate+’s outstanding 98.6% success rate in the post-market clinical study.
Consequently, the product’s high-quality performance is motivating BioHorizons to pursue expansion into other large, attractive markets where they have established accounts and distribution networks.”